Xudong Yin, Ph.D., has been Head of Novartis Pharmaceuticals (APMA Region-Asia Pacific, Middle East and Africa) and President of Novartis Group (China) since April 1, 2017. He is a member of the Novartis Pharma Executive Committee.
Mr. Yin joined Novartis in January 2011 as Chairman of Novartis Group (China) and has been instrumental in the business growth of Novartis Group and all its divisions (including Novartis Pharmaceuticals, Sandoz and Alcon) in China.
Prior to joining Novartis, Mr. Yin served as President, AstraZeneca China (including Mainland and Hong Kong), and successfully led AstraZeneca China to grow into a USD 1 billion business. Before AstraZeneca, He worked at the Boston Consulting Group, focusing on pharmaceutical industry clients in Asia.
Mr. Yin received his Bachelor’s degree in Biochemistry from Beijing University, MBA from Harvard Business School, and PhD in Biological Science from Stanford University.